The Drug Enforcement Administration (DEA) issued a notice on April 28, 2025, correcting a previous document published in the Federal Register on March 26, 2025. The initial document contained incorrect information about a registrant's plans related to controlled substances. The correction specifies that Pharmaron Manufacturing Services intends to bulk manufacture Noroxymorphone as an intermediate product for its customers, using Oxymorphone as a starting material. The corrected notice also clarifies that no other activities involving these substances are authorized for this registration.
Simple Explanation
The government had to fix a mistake they made in a notice about a company that makes certain special medicines. Originally, they gave wrong details about what medicine the company wanted to make, so now they've corrected it to say the company plans to make a specific medicine for others to use in making more medicines.